“It is both an honor and a privilege to be given the opportunity to once again serve as acting director of the National Cancer Institute, following the departure of Dr. Ned Sharpless, who has been asked by the administration to serve as acting commissioner of the Food and Drug Administration.”
“As his deputy, it was a pleasure to work closely with Ned, and I wish him the very best in his new role. I also feel the cancer research community owes him an enormous debt of gratitude for his exemplary leadership of NCI over the past year and a half, and for the course he’s set during this time of extraordinary interest and progress in cancer research…” Read the full post here.
Source: Ensuring a Smooth Leadership Transition at NCI – By Douglas R. Lowy, April 10, 2019. NCI.
